BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Voisin T, Firar AE, Rouyer‐fessard C, Gratio V, Laburthe M. A hallmark of immunoreceptor, the tyrosine‐based inhibitory motif ITIM, is present in the G protein‐coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism. FASEB j 2008;22:1993-2002. [DOI: 10.1096/fj.07-098723] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: a new concept in CNS disorders? ChemMedChem 2010;5:1197-214. [PMID: 20544785 DOI: 10.1002/cmdc.201000132] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 5.0] [Reference Citation Analysis]
2 Kim M, Park H, Kim S, Choi YK, Shin HK, Jeon J, Jang H, Yun I, Bae S, Bae M. Angiogenic role of orexin-A via the activation of extracellular signal-regulated kinase in endothelial cells. Biochemical and Biophysical Research Communications 2010;403:59-65. [DOI: 10.1016/j.bbrc.2010.10.115] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
3 Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget 2018;9:6952-67. [PMID: 29467942 DOI: 10.18632/oncotarget.24084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 El Firar A, Voisin T, Rouyer-fessard C, Ostuni MA, Couvineau A, Laburthe M. Discovery of a functional immunoreceptor tyrosine‐ based switch motif in a 7‐transmembrane‐spanning receptor: role in the orexin receptor OX1R‐driven apoptosis. FASEB j 2009;23:4069-80. [DOI: 10.1096/fj.09-131367] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
5 Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood 2012;119:5512-21. [PMID: 22427202 DOI: 10.1182/blood-2011-10-386805] [Cited by in Crossref: 149] [Cited by in F6Publishing: 154] [Article Influence: 14.9] [Reference Citation Analysis]
6 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
7 Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol (1985) 2013;115:954-71. [PMID: 23640599 DOI: 10.1152/japplphysiol.00700.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
8 Kukkonen JP, Leonard CS. Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 2014;171:314-31. [PMID: 23902572 DOI: 10.1111/bph.12324] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 13.0] [Reference Citation Analysis]
9 Intes L, Bahut M, Nicole P, Couvineau A, Guette C, Calenda A. Intestinal cell targeting of a stable recombinant Cu–Zn SOD from Cucumis melo fused to a gliadin peptide. Journal of Biotechnology 2012;159:99-107. [DOI: 10.1016/j.jbiotec.2012.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
11 Philpott N, Bakken T, Pennell C, Chen L, Wu J, Cannon M. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor contains an immunoreceptor tyrosine-based inhibitory motif that activates Shp2. J Virol 2011;85:1140-4. [PMID: 21047965 DOI: 10.1128/JVI.01362-10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Laburthe M. [How to turn a silent proapoptotic gene in a potent antitumoral target in colorectal cancer]. Med Sci (Paris) 2012;28:272-3. [PMID: 22480651 DOI: 10.1051/medsci/2012283015] [Reference Citation Analysis]
13 Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. Nat Cell Biol 2014;16:728-36. [PMID: 25082195 DOI: 10.1038/ncb3005] [Cited by in Crossref: 159] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
14 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
15 Lapointe F, Turcotte S, Véronneau S, Rola-Pleszczynski M, Stankova J. Role of Protein Tyrosine Phosphatase Epsilon (PTPε) in Leukotriene D4-Induced CXCL8 Expression. J Pharmacol Exp Ther 2019;369:270-81. [PMID: 30867226 DOI: 10.1124/jpet.118.255422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Pruvot B, Laurens V, Salvadori F, Solary E, Pichon L, Chluba J. Comparative analysis of nonaspanin protein sequences and expression studies in zebrafish. Immunogenetics 2010;62:681-99. [PMID: 20820770 DOI: 10.1007/s00251-010-0472-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
17 Blais A, Drouin G, Chaumontet C, Voisin T, Couvelard A, Even PC, Couvineau A. Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS One 2017;12:e0169908. [PMID: 28085909 DOI: 10.1371/journal.pone.0169908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
18 Kukkonen JP. Orexin/Hypocretin Signaling. Curr Top Behav Neurosci 2017;33:17-50. [PMID: 27909990 DOI: 10.1007/7854_2016_49] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
19 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
20 Blais A, Fan C, Voisin T, Aattouri N, Dubarry M, Blachier F, Tomé D. Effects of lactoferrin on intestinal epithelial cell growth and differentiation: an in vivo and in vitro study. Biometals 2014;27:857-74. [PMID: 25082351 DOI: 10.1007/s10534-014-9779-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
21 Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, Jordan CT, Gotlib J, Hsi ED, Abo A. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia 2009;23:1587-97. [DOI: 10.1038/leu.2009.99] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
22 Adeghate E, Fernandez-Cabezudo M, Hameed R, El-Hasasna H, El Wasila M, Abbas T, Al-Ramadi B. Orexin-1 receptor co-localizes with pancreatic hormones in islet cells and modulates the outcome of streptozotocin-induced diabetes mellitus. PLoS One 2010;5:e8587. [PMID: 20062799 DOI: 10.1371/journal.pone.0008587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
23 Duguay D, Bélanger-Nelson E, Mongrain V, Beben A, Khatchadourian A, Cermakian N. Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One 2011;6:e26430. [PMID: 22028875 DOI: 10.1371/journal.pone.0026430] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
24 Gingell JJ, Hendrikse ER, Hay DL. New Insights into the Regulation of CGRP-Family Receptors. Trends in Pharmacological Sciences 2019;40:71-83. [DOI: 10.1016/j.tips.2018.11.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
25 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
26 Laburthe M, Voisin T, El Firar A. Orexins/hypocretins and orexin receptors in apoptosis: a mini-review. Acta Physiologica 2010;198:393-402. [DOI: 10.1111/j.1748-1716.2009.02035.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
27 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
29 Leonard CS, Kukkonen JP. Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol 2014;171:294-313. [PMID: 23848055 DOI: 10.1111/bph.12296] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 10.3] [Reference Citation Analysis]
30 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
31 Jäntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP. OX1 orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol 2012;165:1109-23. [PMID: 21718304 DOI: 10.1111/j.1476-5381.2011.01565.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
32 Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47-60. [PMID: 21193867 DOI: 10.1038/nrd3320] [Cited by in Crossref: 475] [Cited by in F6Publishing: 451] [Article Influence: 43.2] [Reference Citation Analysis]
33 Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U, Puccetti P. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A 2008;105:20828-33. [PMID: 19088199 DOI: 10.1073/pnas.0810278105] [Cited by in Crossref: 131] [Cited by in F6Publishing: 131] [Article Influence: 9.4] [Reference Citation Analysis]